Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Grassley whistleblower letter

This article was originally published in The Tan Sheet

Executive Summary

Sen. Chuck Grassley (R-Iowa) asks FDA to "address allegations that administrative action may be taken against" agency whistleblower David Graham, MD, "including that he may be terminated or transferred against his wishes to a job other than conducting scientific research," in a Nov. 29 letter to Acting Commissioner Lester Crawford, PhD. Graham, associate director for science at FDA's Office of Drug Safety, testified at a Nov. 18 Senate Finance Committee hearing on Vioxx (1"The Tan Sheet" Nov. 22, 2004, p. 15)...
Advertisement

Related Content

Vioxx Hearing Witnesses Push For Independent Drug Safety Office
Vioxx Hearing Witnesses Push For Independent Drug Safety Office

Topics

Advertisement
UsernamePublicRestriction

Register

PS097594

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel